The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

Eli Lilly has said it is seeking permission to ... currently headed by amyloid-targeting drug donanemab which was filed for FDA approval in the IUS last October. The announcement is another ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy from ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

The new drug was developed by Eli Lilly, the same company behind donanemab, and can be self-injected, like some diabetes medications. It is administered every one to two months and patients in the ...

Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well, ...

Royal Melbourne Hospital (RMH) is one of more than a dozen sites around Australia taking part in the major global trial for ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...